# US 2026/0294966 A1 · Process of Manufacturing a Platelet Releaseate Derivative and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0294966 A1
- Document ID: US20260294966A1
- Status: Published application
- Kind: A1
- Application number: 19/480,732
- Filed: 2024-05-03
- Published: 2026-10-01
- Earliest claimed: 2023-05-03
- Assignees: Tecbiocel S.L.
- Applicants: Tecbiocel S.L.
- Inventors: Federico GONZÁLEZ POZAS; Ainhoa FERNÁNDEZ SAN MIGUEL; Ander ABARRATEGI LÓPEZ; Antonio MOSCARDÓ MARTÍNEZ
- Web page: https://patentgrep.com/patent/US20260294966A1

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/19: Platelets; Megacaryocytes
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention generally refers to a method (from hereinafter method of the invention) for obtaining a composition comprising a blood derivative or blood derived products, preferably a platelet releasate or platelet releasate derivative, particularly suitable for allogenic use, comprising the steps of: a) mixing platelet-rich plasma (hereinafter referred to as “PRP”) obtained by centrifugation of an anticoagulated sample of whole blood, bone marrow, menstrual fluid, or umbilical cord blood, with a formulation agent (FA) at a ratio PRP:FA of from 1:1 to 1:10, wherein the formulation agent is selected from a pharmaceutically acceptable excipient or a pharmaceutically acceptable additive; b) activating the platelet rich plasma (PRP) resultant from step (a); c) centrifuging the product resultant from step (b) in the range of from 100 g to 6000 g, for a time of between 5 and 30 minutes, at a temperature between 4° C. and 25° C., d) incubating the product resultant from step (c) at a temperature range between about 50° C. to about 62° C. for a time range between about 30 minutes and about 90 minutes; e) removing clot remains and cellular and platelet debris from the product resultant from step (d) by preferably carrying out a clarification and/or filtration step of the product resultant from step (d), and f) Collecting the composition resultant from step (e).

## Claims

### Claim 1

A method of obtaining a composition comprising a platelet releasate derivative, comprising the steps of:
a) mixing platelet-rich plasma (hereinafter referred to as “PRP”) obtained by centrifugation of an anticoagulated sample of whole blood, bone marrow, menstrual fluid, or umbilical cord blood, with a formulation agent (FA) at a ratio PRP:FA of from 1:1 to 1:10, wherein the formulation agent is selected from a pharmaceutically acceptable excipient or a pharmaceutically acceptable additive;
b) activating the platelet rich plasma (PRP) resultant from step (a);
c) centrifuging the product resultant from step (b) in the range of from 100 g to 6000 g, for a time of between 5 and 30 minutes, at a temperature between 4° C. and 25° C.,
d) incubating the product resultant from step (c) at a temperature range between about 50° C. to about 62° C. for a time range between about 30 minutes and about 90 minutes;
e) removing clot remains and cellular and platelet debris from the product resultant from step (d) by preferably carrying out a clarification and/or filtration step of the product resultant from step (d), and
f) collecting the composition resultant from step (e);
wherein the FA is a pharmaceutically acceptable excipient selected from the group consisting of physiological saline, Ringer's lactate, phosphate buffered saline, Hanks's solution, Hartmann's solution, glucosaline, serum (autologous, heterologous, allogeneic), albumin and platelet additive solutions (PAS); and
wherein the activation of the platelet rich plasma (PRP) is carried out by temperature activation and/or the addition of activating components such as the addition of a calcium salt to the product resultant from step a) such as calcium chloride, calcium gluconate, calcium lactate, calcium citrate, calcium carbonate or any combination thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein step d) is carried out by incubating the product resultant from step (c) at a temperature range between about 56° C. to about 62° C. for a time range between 30 minutes and 90 minutes.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2, wherein step c) is performed by centrifuging the product resultant from step (b) in the range of from about 500 g to about 2500 g, for a time of between 5 and 20 minutes, at a temperature between 15° C. and 25° C.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the calcium salt shall be added to the product resultant from step a) at a final concentration of between 0.05 mM to 50 mM.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the method comprises the following steps:
a) mixing platelet-rich plasma (hereinafter referred to as “PRP”) obtained by centrifugation of an anticoagulated sample of whole blood, Bone marrow, Menstrual fluid, or Umbilical cord blood, with a formulation agent (FA) at a ratio PRP:FA of about 1:2, wherein the formulation agent is selected from the list consisting of physiological saline, Ringer's lactate, phosphate buffered saline, Hanks's solution, Hartmann's solution, glucosaline, serum (autologous, heterologous, allogeneic), platelet additive solutions (PAS) and albumin;
b) activating the platelet rich plasma (PRP) resultant from step (a) by the addition of a calcium salt to the product resultant from step a) such as calcium chloride, calcium gluconate, calcium lactate, calcium citrate, calcium carbonate or any combination thereof at a final concentration of between 0.05 mM to 50 mM;
c) centrifuging the product resultant from step (b) in the range of from 100 g to 6000 g, for a time of between 5 and 30 minutes, at a temperature between 4° C. and 25° C.,
d) incubating the product resultant from step (c) at a temperature range between about 50° C. to about 62° C. for a time range between about 30 minutes and about 90 minutes;
e) removing clot remains and cellular and platelet debris from the product resultant from step (d) by preferably carrying out a clarification and/or filtration step of the product resultant from step (d), and
f) collecting the composition resultant from step (e).

### Claim 6 (depends on 5)

The method of claim 5, wherein step (b) is carried by adding calcium chloride to the product resultant from step (a) at a final concentration of about 22.5 mM.

### Claim 7 (depends on 5)

The method of claim 5, wherein the formulation agent of step (a) is selected from the list consisting of physiological saline, Ringer's lactate, phosphate buffered saline, serum and albumin, and wherein step (b) is carried by adding calcium chloride to the product resultant from step (a) at a final concentration of about 22.5 mM.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the method further comprises, preferably after step (e) or (f), the addition of a therapeutic agent such as mesenchymal stem cells (MSCs), preferably MSCs derived from adipose tissue, bone marrow, dental pulp, umbilical cord, amniotic fluid, synovial fluid/membrane, liver, spleen, testicles, menstrual blood, dermis, skeletal muscle, periosteum, lung, and/or peripheral blood, steroids, chondrogenic stimulating factors, monosaccharides, oligosaccharides, polysaccharides, glycosaminoglycans, collagen, essential fatty acids, or trophic factors.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A composition obtained or obtainable by the method of any one of claims 1 to 8.

### Claim 10 (depends on 9)

A composition, preferably a pharmaceutical composition, comprising the composition of claim 9 and further comprising any one or more of the following emollients (such as aloe vera), absorbents (such as cellulose), anti-aggregants (such as silicon), anti-dandruff (such as clotrimazole), anti-foaming agents (such as dimethicone), anti-microbial (such as hydrogen peroxide), antioxidant (such as hydroquinone), antiseborrheic (such as Quercus extract), antistatic (such as polyethylene), astringent (such as rosehip oil), binders (such as dextrans), whitener (such as hydroquinone), buffers (such as citric acid), volumizing agents (such as kaolin), chelating agents (such as EDTA), cleansing agent (such as lauric acid), cosmetic colorant (such as riboflavin), denaturant (such as eucalyptus), deodorant (such as perfume), emulsifiers (such as capric acid), emulsion stabilizers (such as pectin), film-forming agents (such as chitosan), gelling agents (such as carbomers), hair conditioners (such as casein), humectants (such as lactic acid), and/or hydrotropes (such as toluene sulfonic acid).

### Claim 11 (depends on 9, 10)

The composition of claim 9 or the composition of claim 10, wherein any of the said compositions are comprised or in the form of a hydrogel, gel, cream, polymer, fiber/mesh, foam, serum, or base inks for 3D/4D/5D printing.

### Claim 12 (depends on 9, 10, 11)

The composition according to any one of claims 9 to 11, for use in therapy.

### Claim 13 (depends on 9, 10, 11)

The composition according to any one of claims 9 to 11, for use in the treatment of alopecia or in the treatment of an inflammatory skin disorder.
